OceansBio오션스바이오
332190 · KONEX · ₩332190 · 오션스바이오
- Market cap
- ₩3.1B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−73.5% from the high
₩870Today: ₩2,100 – ₩2,100₩7,930
Returns
- 1W−7.7%
- 1M−16.5%
- 3M−22.5%
- 6M+16.0%
- YTD−44.7%
- 1Y−58.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 1,477,839
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumWeak-16.5% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
OceansBio stock overview
OceansBio (오션스바이오, KRX: 332190) is listed on KONEX, in the Medical & precision devices sector. The company manufactures medical devices, focusing on electroceuticals, which are electronic devices that use electrical, magnetic, or other physical stimulation to treat conditions such as epilepsy and depression. Its shares closed at ₩2,100 on Oct 29, 2026, down 4.33% on the day, giving it a market value of ₩3.1B.
Key facts
- Market cap
- ₩3.1B
- Sector
- Medical & precision devices
- Latest price change
- −4.33%
- As of
- Oct 29, 2026
- Main business
- The company manufactures medical devices, focusing on electroceuticals, which are electronic devices that use electrical, magnetic, or other physical stimulation to treat conditions such as epilepsy and depression.
Quick answers about OceansBio
- What does OceansBio do?
- The company manufactures medical devices, focusing on electroceuticals, which are electronic devices that use electrical, magnetic, or other physical stimulation to treat conditions such as epilepsy and depression. The filing describes a market for implantable and non-invasive neuromodulation devices, including vagus nerve stimulation, and notes the business is positioned within South Korea's medical device industry.
- What is the market cap of OceansBio?
- The market capitalisation of OceansBio was ₩3.1B at the close on Oct 29, 2026.
- Who are the largest shareholders of OceansBio?
- According to the latest official filings, the largest reported holders are Lee Hyeon-woong (56.34%, as of Apr 4, 2025); Capstone Partners (10.07%, as of Apr 1, 2026); BNK Venture Investment (6.54%, as of Jan 22, 2025).
- When is the next earnings report from OceansBio?
- Korean companies rarely announce results dates in advance. Based on when OceansBio filed the same report in past years, its next annual results is expected between Mar 10, 2027 and Mar 18, 2027.
Company profile
The company manufactures medical devices, focusing on electroceuticals, which are electronic devices that use electrical, magnetic, or other physical stimulation to treat conditions such as epilepsy and depression. The filing describes a market for implantable and non-invasive neuromodulation devices, including vagus nerve stimulation, and notes the business is positioned within South Korea's medical device industry.
Written by AI from the company's latest annual report.
- Korean name
- 오션스바이오
- Themes
- Biotech (new drugs)
- CEO
- 이현웅
- Founded
- Jul 2018
- Listed
- Jan 2025
- Listed shares
- 1,477,839
- Fiscal year ends
- Month 12
- Website
- oceansbio.com/
Similar companies
- TSE131290 · ₩2.9T₩260,500−5.27%
- Kctech281820 · ₩1.9T₩97,500+2.09%
- Classys214150 · ₩1.7T₩26,800−0.74%
- Park Systems140860 · ₩1.6T₩228,500−0.44%
- DI003160 · ₩1.2T₩43,500+0.46%
- Curiox Biosystems445680 · ₩1T₩60,600−2.88%
- LivsMed491000 · ₩1T₩40,450−7.33%
- Seers458870 · ₩907B₩23,650−3.86%
Recent filings
See all- Securities Issuance Results (Voluntary Disclosure) (Third-Party Allotment Rights Offering)Oct 22, 2026
- Rights offering (paid-in capital increase) decisionOct 14, 2026
- Investor relations (IR) eventOct 6, 2026
- Investor relations (IR) eventSep 18, 2026
- Investor relations (IR) eventJul 1, 2026
Titles in Korean until English translations are added.
Also known as: OceansBio / 오션스바이오 / 332190 / KRX:332190
Source: KRX statistical information